A previous study has shown an efficient, systemic transgene expression
in mice via intravenous administration of a LPD formulation composed
of DOTAP liposomes, protamine sulfate and plasmid DNA. In this study,
factors affecting the in vivo performance of this formulation were fur
ther evaluated. A protocol in which liposomes were mixed with protamin
e before the addition of plasmid DNA was shown to produce small conden
sed particles with a diameter of about 135 nm. These particles were st
able over time and gave a high level of gene expression in all tissues
examined including lung, heart, spleen, liver and kidney with the hig
hest level of expression in the lung. Inclusion of dioleoylphosphatidy
lethanolamine (DOPE) as a helper lipid significantly decreased the in
vivo activity of LPD. In contrast inclusion of cholesterol as a helper
lipid increased the in vivo transfection efficiency of LPD and more i
mportantly, decrease the amount of cationic lipid required for the max
imal level of gene expression. Studies on the interaction between mous
e serum and LPD showed that LPD became negatively charged after exposu
re to serum, and LPDs containing different helper lipids varied in the
amount of associated serum proteins. LPD containing DOPE was more enr
iched in a protein corresponding to albumin in molecular weight. These
results suggest that the mechanism of LPD-mediated intravenous gene d
elivery might be different from that of in vitro lipofection and that
serum protein association might be a major factor limiting the in vivo
transfection by LPD.